Sevelamer: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CONITEC (Brazil), HAS (France) and PBAC (Australia), among others, recommended or restricted sevelamer, while AWMSG (Wales) and PHARMAC (New Zealand) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded restricted for “Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease.”, while AWMSG (Wales) recorded not recommended for “for control of hyperphosphataemia in paediatric patients (> 6 years of age and a body surface area (BSA) of > 0.75 m2) w…”.
The file has been open for more than a decade: 15.2 years separate the first record, 10 Dec 2007 at SMC (Scotland), from the most recent, 17 Mar 2023 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: not recommended on 10 Dec 2007, restricted by 12 Feb 2018, after a resubmission.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The programme is broad: 9 distinct indication wordings are recorded for sevelamer by the agencies that label one in English (AWMSG, PBAC and SMC).
4 of these 19 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess sevelamer, on 10 Dec 2007; CONITEC (Brazil) did not open a file until 14 Apr 2022 — an unusually long tail of 14.3 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 12 years in total.
5 of the 7 agencies here assessed sevelamer more than once, HAS (France) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
7 of the 18 agencies in this archive hold a record for sevelamer.
The full ledger for sevelamer reads 8 recommended, 4 other, 4 not recommended and 2 restricted, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 17 Mar 2023 | Chronic kidney disease | PTAC advice: No Formal Recommendation | source |
| CONITEC (Brazil) | 14 Apr 2022 | Tratamento da hiperfosfatemia em pacientes com doença renal crônica estágio 5D. | incorporated into SUS | source |
| PBAC (Australia) | 2021 | Chronic kidney disease | Recommendation extended for 6 months | source |
| HAS (France) | 4 Mar 2020 | Indication extension | SMR substantial · ASMR V | source |
| SMC (Scotland) | 12 Feb 2018 | Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m2) with chronic kidney disease. | accepted (restricted) | source |
14 further decisions for sevelamer, across 6 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- deferasirox — same ATC class V03A — Other therapeutic products
- patiromer — same ATC class V03A — Other therapeutic products
- deferiprone — same ATC class V03A — Other therapeutic products
- difelikefalin — same ATC class V03A — Other therapeutic products
- naloxone — same ATC class V03A — Other therapeutic products
- andexanet alfa — same ATC class V03A — Other therapeutic products
Coverage: 19 decisions for sevelamer from 7 agencies, 2007 to 2023. Data to 7 Sep 2026. ATC class V03A — Other therapeutic products. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.